文献速递临床试验与 GCP医学人工智能与信息学真实世界研究与卫生经济

利用移动健康改善高血压合并双相障碍患者的服药依从性并降低血压(iTAB-CV):两阶段随机临床试验的研究方案

Using mHealth to improve adherence and reduce blood pressure in individuals with hypertension and bipolar disorder (iTAB-CV): study protocol for a 2-stage randomized clinical trial.
PubMed 文献 · Trials · 2022-06-29

主要结局为收缩压和抗高血压药物依从性,随访52周,旨在评估远程干预对该高危人群血压和精神症状控制的作用。

要点

  • 高血压合并双相障碍患者心血管病高发且管理不佳,服药依从性障碍突出。
  • 干预组接受每日短信(覆盖11个领域)加定制信息2个月,随后再随机分为高或低强化阶段2个月。
  • 主要结局为收缩压和抗高血压药物依从性,采用自报问卷并以自动药丸监测装置验证。

核心结论

  • 该远程干预可能有助于推进这一高危人群的照护,并易于推广和适配其他服药依从性差的人群。
  • 研究设计包含实施要素,旨在为未来扩大规模提供信息。

研究设计与样本

  • 干预组(N=100)接受通过交互式短信推送的简短实用依从性干预,联合服药、情绪和家庭血压自我监测;对照组(N=100)仅接受自我监测。
  • 随机化前所有参与者观看强调高血压和双相障碍药物治疗重要性的教育视频。
  • 干预组先接受每日预定内容短信(覆盖11个领域)加定制信息2个月,随后再次随机分为高强化(从每日逐渐减至每周短信)或低强化(每周短信)阶段2个月。
  • 所有参与者随访52周。

主要发现

  • 主要结局为收缩压和抗高血压药物依从性,依从性由自报问卷确定并以自动药丸监测装置验证。
  • 次要结局包括双相障碍药物依从性、精神症状、健康状况、服药行为自我效能、疾病信念、药物态度和习惯强度。
  • 有前景的试点数据和以习惯形成为背景看待持续服药行为的理论模型提示该干预可能有效。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiovascular disease in individuals with mental health conditions such as bipolar disorder is highly prevalent and often poorly managed. Individuals with bipolar disorder face significant medication adherence barriers, especially when they are prescribed multiple medications for other health conditions including hypertension. Poor adherence puts them at a disproportionate risk for poor health outcomes. As such, there is a need for effective interventions to improve hypertension medication adherence, particularly in patients that struggle with adherence due to mental health comorbidity. METHODS: This 5-year project uses a 2-stage randomized controlled trial design to evaluate a brief, practical adherence intervention delivered via interactive text messaging (iTAB-CV) along with self-monitoring of medication taking, mood, and home blood pressure (N = 100) compared to self-monitoring alone (N = 100). Prior to randomization, all participants will view an educational video that emphasizes the importance of medication for the treatment of hypertension and bipolar disorder. Those randomized to the texting intervention will receive daily text messages with predetermined content to address 11 salient domains as well as targeted customized messages for 2 months. This group will then be re-randomized to receive either a high (gradual taper from daily to weekly texts) or low booster (weekly texts) phase for an additional 2 months. All participants will be monitored for 52 weeks. The primary outcomes are systolic blood pressure and adherence to antihypertensive medication as determined by a self-reported questionnaire and validated with an automated pill-monitoring device. Secondary outcomes include adherence to bipolar disorder medications, psychiatric symptoms, health status, self-efficacy for medication-taking behavior, illness beliefs, medication attitudes, and habit strength. DISCUSSION: This study specifically targets blood pressure and mental health symptom control in people with bipolar and includes implementation elements in the study design intended to inform future scale-up. Promising pilot data and a theoretical model, which views sustained medication-taking behavior in the context of habit formation, suggests that this remotely delivered intervention may help advance care for this high-risk population and is amenable to both scale up and easy adaptation for other groups with poor medication adherence. TRIAL REGISTRATION: The study was registered at ClinicalTrials.gov ( NCT04675593 ) on December 19, 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Levin JB, Moore DJ, Depp C, et al. Using mHealth to improve adherence and reduce blood pressure in individuals with hypertension and bipolar disorder (iTAB-CV): study protocol for a 2-stage randomized clinical trial. Trials. 2022. PMID: 35768875. doi:10.1186/s13063-022-06449-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。